Award
National Cancer Institute 5P01CA065493-29
"Off-the-Shelf" iPSC-Derived Regulatory T Cell Immunotherapeutics
Recipient
University of Minnesota
Award Amount
$595,443.00
Ceiling
$595,443.00
Awarded
July 28, 2026
Identifier
5P01CA065493-29
This award funds the development of an innovative CAR T-cell therapy derived from induced pluripotent stem cells (iPSCs) to treat AML by preventing complications of allogeneic hematopoietic cell transplantation and targeting AML cells with reduced toxicity and improved efficacy.
Description
Development of a non-toxic, tunable off-the-shelf chimeric antigen receptor (CAR) cell-based immunotherapy to treat acute myelogenous leukemia (AML) using gene-edited human iPSCs producing CD8 T cells designed to avoid rejection and exhaustion while retaining graft-versus-host disease (GVHD) and graft-versus-leukemia (GVL) functions.